A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma - Concepedia

Concepedia

Publication | Open Access

A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma

DOI Full Paper Access

15

Citations

26

References

2022

Year

Pengcheng He, Haibo Liu, Bryan Zimdahl, Jie Wang, Minna Luo, Qi Chang, Fangzhou Tian, Ni Fan, Duo Yu, Huasheng Liu,

Journal of Cancer Research and Clinical Oncology

References

	Year	Citations

Page 1